Protocol Ledger

NCT05780424 · Phase III · COMPLETED

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Interventional Phase III clinical trial protocol NCT05780424 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-16 Enrollment: 353 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05780424
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)353 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05780424
Protocol FieldVerified Registry Value
NCT IdentifierNCT05780424
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment353 participants (ACTUAL)
Registered Start Date2020-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05780424
Hospital Research SiteLocationSite Profile
USC Norris Comprehensive Cancer Center and Keck MedicineLos Angeles, CAOpen Hospital Dossier ->
Cedars-Sinai Medical CenterLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI